期刊
CURRENT HYPERTENSION REPORTS
卷 15, 期 5, 页码 458-469出版社
SPRINGER
DOI: 10.1007/s11906-013-0381-0
关键词
Kidney transplantation; Hypertension; Post-transplant hypertension; Ambulatory blood pressure monitoring; Self-blood pressure monitoring; Immunosuppression; Calcineurin inhibitor; Glucocorticoids; Donor risk factors; Recipient risk factors; Antihypertensives; Cardiovascular outcomes; Transplant renal artery stenosis; Hypertension management; Interstitial fibrosis/tubular atrophy; Pathophysiology of hypertension
资金
- Astellas Pharma
- Novartis
Post-transplant hypertension is associated with decreased graft and patient survival and cardiovascular morbidity. Unfortunately, post-transplant hypertension is often poorly controlled. Important risk factors include immunosuppressive medications, complications of the transplant surgery, delayed graft function, rejection, and donor and recipient risk factors. The effects of immunosuppressive medications are multifactorial including increased vascular and sympathetic tone and salt and fluid retention. The immunosuppressive agents most commonly associated with hypertension are glucocorticoids and calcineurin inhibitors. Drug therapy for hypertension should be based on the comorbidities and pathophysiology. Evidence-based approaches to defining and treating hypertension in renal transplant recipients are predominantly extrapolated from large-scale studies performed in the general population. Thus, there continues to be a need for larger studies examining the pathophysiology, diagnosis and treatment of hypertension in renal transplant recipients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据